Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Fluorodeoxyglucose F18 | 42 | 2023 | 2016 | 4.820 |
Why?
|
Radiopharmaceuticals | 38 | 2024 | 2645 | 2.390 |
Why?
|
Inflammatory Breast Neoplasms | 9 | 2021 | 143 | 2.170 |
Why?
|
Positron-Emission Tomography | 47 | 2023 | 6234 | 1.980 |
Why?
|
Organometallic Compounds | 4 | 2022 | 665 | 1.380 |
Why?
|
Neuroendocrine Tumors | 5 | 2023 | 594 | 1.330 |
Why?
|
Radium | 5 | 2020 | 65 | 1.250 |
Why?
|
Lutetium | 3 | 2023 | 32 | 1.160 |
Why?
|
Dipeptides | 4 | 2023 | 409 | 1.150 |
Why?
|
Octreotide | 4 | 2022 | 145 | 1.120 |
Why?
|
Heterocyclic Compounds, 1-Ring | 3 | 2023 | 65 | 1.120 |
Why?
|
Adipose Tissue, Brown | 4 | 2021 | 757 | 1.070 |
Why?
|
Nuclear Medicine | 6 | 2023 | 233 | 1.050 |
Why?
|
Tomography, X-Ray Computed | 29 | 2023 | 20129 | 1.040 |
Why?
|
Radioimmunotherapy | 7 | 2013 | 91 | 1.000 |
Why?
|
Prostate-Specific Antigen | 9 | 2024 | 2494 | 1.000 |
Why?
|
Lymphoma | 7 | 2017 | 1877 | 0.990 |
Why?
|
Hodgkin Disease | 4 | 2022 | 1415 | 0.980 |
Why?
|
Bone Neoplasms | 6 | 2020 | 2529 | 0.980 |
Why?
|
Dihydrotestosterone | 2 | 2023 | 190 | 0.970 |
Why?
|
Receptors, Peptide | 2 | 2022 | 272 | 0.780 |
Why?
|
Cyclobutanes | 1 | 2020 | 59 | 0.700 |
Why?
|
Carboxylic Acids | 1 | 2020 | 97 | 0.700 |
Why?
|
Ribs | 1 | 2021 | 252 | 0.700 |
Why?
|
Mouth Neoplasms | 2 | 2022 | 601 | 0.690 |
Why?
|
Prostatic Neoplasms | 8 | 2024 | 11124 | 0.660 |
Why?
|
Hematologic Neoplasms | 2 | 2021 | 1832 | 0.620 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2023 | 1378 | 0.560 |
Why?
|
Diagnostic Imaging | 5 | 2017 | 3507 | 0.560 |
Why?
|
Carcinoma, Lobular | 1 | 2020 | 484 | 0.530 |
Why?
|
Radionuclide Imaging | 8 | 2023 | 2031 | 0.530 |
Why?
|
Neoplasm Recurrence, Local | 11 | 2024 | 9239 | 0.520 |
Why?
|
Biological Products | 1 | 2024 | 860 | 0.500 |
Why?
|
Molecular Imaging | 2 | 2012 | 828 | 0.500 |
Why?
|
Radioisotopes | 6 | 2023 | 499 | 0.490 |
Why?
|
Patient Care Planning | 1 | 2020 | 921 | 0.490 |
Why?
|
Radiometry | 6 | 2023 | 800 | 0.480 |
Why?
|
Stem Cell Transplantation | 3 | 2023 | 1620 | 0.460 |
Why?
|
Breast Neoplasms | 8 | 2023 | 20822 | 0.460 |
Why?
|
Salvage Therapy | 3 | 2024 | 1275 | 0.440 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.420 |
Why?
|
Radiotherapy | 3 | 2018 | 1533 | 0.420 |
Why?
|
Neoplasms | 12 | 2024 | 21683 | 0.410 |
Why?
|
Blood Glucose | 3 | 2018 | 6256 | 0.410 |
Why?
|
Humans | 112 | 2024 | 744343 | 0.410 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 4851 | 0.410 |
Why?
|
Parathyroid Neoplasms | 2 | 2010 | 245 | 0.400 |
Why?
|
Colon | 1 | 2019 | 1772 | 0.380 |
Why?
|
Head and Neck Neoplasms | 3 | 2022 | 2734 | 0.370 |
Why?
|
Carcinoma | 5 | 2021 | 2375 | 0.360 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2009 | 1107 | 0.340 |
Why?
|
Antibodies, Monoclonal | 6 | 2017 | 9274 | 0.340 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5442 | 0.330 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 4034 | 0.330 |
Why?
|
Genital Neoplasms, Female | 1 | 2014 | 523 | 0.320 |
Why?
|
Neoplasm Staging | 10 | 2023 | 11031 | 0.310 |
Why?
|
Transplantation, Autologous | 4 | 2023 | 2124 | 0.310 |
Why?
|
Prostate | 4 | 2024 | 1774 | 0.310 |
Why?
|
Endometrial Neoplasms | 1 | 2017 | 1353 | 0.310 |
Why?
|
Hyperparathyroidism | 1 | 2008 | 339 | 0.300 |
Why?
|
Neck Muscles | 1 | 2007 | 104 | 0.300 |
Why?
|
Retrospective Studies | 29 | 2022 | 77449 | 0.290 |
Why?
|
Immunotherapy | 3 | 2022 | 4445 | 0.290 |
Why?
|
Diagnosis, Differential | 9 | 2020 | 12959 | 0.280 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4262 | 0.280 |
Why?
|
Intercostal Muscles | 1 | 2004 | 26 | 0.260 |
Why?
|
Male | 50 | 2024 | 350118 | 0.250 |
Why?
|
Middle Aged | 46 | 2023 | 213383 | 0.250 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 11524 | 0.250 |
Why?
|
Lymphatic Diseases | 1 | 2006 | 324 | 0.250 |
Why?
|
Adult | 39 | 2022 | 214055 | 0.240 |
Why?
|
Tissue Distribution | 5 | 2019 | 2327 | 0.240 |
Why?
|
Female | 52 | 2023 | 380194 | 0.230 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2006 | 648 | 0.230 |
Why?
|
Treatment Outcome | 19 | 2022 | 63114 | 0.220 |
Why?
|
Neck | 1 | 2007 | 697 | 0.220 |
Why?
|
Aged | 39 | 2022 | 163280 | 0.220 |
Why?
|
Prostatectomy | 4 | 2024 | 1890 | 0.220 |
Why?
|
Adenoma | 2 | 2010 | 2174 | 0.210 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2924 | 0.210 |
Why?
|
Receptors, Somatostatin | 2 | 2023 | 129 | 0.210 |
Why?
|
Head | 1 | 2007 | 880 | 0.200 |
Why?
|
Adrenocortical Carcinoma | 1 | 2022 | 88 | 0.200 |
Why?
|
Subtraction Technique | 1 | 2004 | 525 | 0.200 |
Why?
|
Taxoids | 2 | 2022 | 666 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2017 | 1770 | 0.200 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 931 | 0.190 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2022 | 162 | 0.190 |
Why?
|
Paraganglioma | 1 | 2022 | 143 | 0.190 |
Why?
|
Prognosis | 7 | 2022 | 29063 | 0.190 |
Why?
|
Radiotherapy Dosage | 6 | 2021 | 2879 | 0.190 |
Why?
|
Gastric Emptying | 1 | 2022 | 233 | 0.180 |
Why?
|
Mastectomy | 4 | 2021 | 1793 | 0.180 |
Why?
|
Receptors, Progesterone | 3 | 2020 | 1097 | 0.180 |
Why?
|
Pheochromocytoma | 1 | 2022 | 337 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.180 |
Why?
|
Education, Medical | 1 | 2012 | 1721 | 0.180 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2018 | 1624 | 0.180 |
Why?
|
Internship and Residency | 3 | 2022 | 5788 | 0.170 |
Why?
|
Cholecystokinin | 1 | 2019 | 114 | 0.170 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2019 | 136 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2018 | 3479 | 0.170 |
Why?
|
Survival Analysis | 4 | 2021 | 10252 | 0.160 |
Why?
|
Thyroid Neoplasms | 2 | 2009 | 2282 | 0.160 |
Why?
|
Body Weight | 1 | 2009 | 4669 | 0.160 |
Why?
|
Neoplasm, Residual | 5 | 2023 | 973 | 0.160 |
Why?
|
Gallbladder | 1 | 2019 | 302 | 0.150 |
Why?
|
Aged, 80 and over | 20 | 2020 | 57776 | 0.150 |
Why?
|
Neoadjuvant Therapy | 5 | 2023 | 2728 | 0.150 |
Why?
|
Parathyroid Glands | 2 | 2010 | 509 | 0.150 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2017 | 876 | 0.150 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2020 | 233 | 0.150 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2017 | 990 | 0.150 |
Why?
|
Receptors, Androgen | 1 | 2023 | 1058 | 0.140 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2022 | 740 | 0.140 |
Why?
|
Crohn Disease | 1 | 2009 | 2303 | 0.140 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2416 | 0.140 |
Why?
|
Whole-Body Irradiation | 1 | 2017 | 449 | 0.140 |
Why?
|
Axilla | 1 | 2018 | 595 | 0.140 |
Why?
|
Uveal Neoplasms | 1 | 2018 | 310 | 0.140 |
Why?
|
Hepatitis C | 1 | 2006 | 1591 | 0.140 |
Why?
|
Oncology Service, Hospital | 1 | 2016 | 57 | 0.130 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2018 | 434 | 0.130 |
Why?
|
Antineoplastic Agents | 6 | 2020 | 13695 | 0.130 |
Why?
|
Intestinal Neoplasms | 2 | 2018 | 319 | 0.130 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2012 | 1381 | 0.130 |
Why?
|
Beta Particles | 1 | 2015 | 50 | 0.130 |
Why?
|
Artifacts | 2 | 2018 | 1904 | 0.130 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2009 | 692 | 0.120 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2187 | 0.120 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 841 | 0.120 |
Why?
|
Remission Induction | 2 | 2017 | 2386 | 0.120 |
Why?
|
Sensitivity and Specificity | 7 | 2010 | 14722 | 0.120 |
Why?
|
Genes, Retinoblastoma | 1 | 2014 | 136 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2022 | 9959 | 0.120 |
Why?
|
Glucose | 2 | 2022 | 4397 | 0.110 |
Why?
|
Triazoles | 1 | 2018 | 911 | 0.110 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8642 | 0.110 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1261 | 0.110 |
Why?
|
Lymphoma, Follicular | 2 | 2013 | 435 | 0.110 |
Why?
|
Vascular Neoplasms | 1 | 2014 | 175 | 0.100 |
Why?
|
Cerebral Hemorrhage | 1 | 2023 | 2647 | 0.100 |
Why?
|
Medical Oncology | 1 | 2024 | 2265 | 0.100 |
Why?
|
Radiology Department, Hospital | 1 | 2016 | 412 | 0.100 |
Why?
|
Ultrasonography, Mammary | 1 | 2013 | 250 | 0.100 |
Why?
|
Sirolimus | 2 | 2009 | 1564 | 0.100 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39050 | 0.100 |
Why?
|
Radiation Dosage | 2 | 2017 | 1928 | 0.090 |
Why?
|
Vena Cava, Inferior | 1 | 2014 | 440 | 0.090 |
Why?
|
Bone Marrow | 3 | 2010 | 2948 | 0.090 |
Why?
|
Imaging, Three-Dimensional | 1 | 2023 | 4042 | 0.090 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 604 | 0.090 |
Why?
|
Epithelial Cells | 1 | 2022 | 3690 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.090 |
Why?
|
Bone Marrow Neoplasms | 1 | 2010 | 104 | 0.090 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 477 | 0.090 |
Why?
|
Mammaplasty | 1 | 2019 | 1204 | 0.090 |
Why?
|
Cold Temperature | 2 | 2010 | 772 | 0.080 |
Why?
|
Oxygen Radioisotopes | 1 | 2008 | 76 | 0.080 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 300 | 0.080 |
Why?
|
Fibrous Dysplasia of Bone | 1 | 2008 | 54 | 0.080 |
Why?
|
Rats, Inbred Lew | 2 | 2010 | 1162 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 7 | 2023 | 35421 | 0.080 |
Why?
|
Ovarian Neoplasms | 2 | 2021 | 4838 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 177 | 0.080 |
Why?
|
Intestinal Mucosa | 1 | 2019 | 3036 | 0.080 |
Why?
|
Patient Education as Topic | 1 | 2018 | 2278 | 0.080 |
Why?
|
Bronchial Neoplasms | 1 | 2008 | 112 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2010 | 235 | 0.080 |
Why?
|
Benzamides | 1 | 2013 | 1379 | 0.080 |
Why?
|
Molecular Mimicry | 1 | 2008 | 201 | 0.080 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2010 | 160 | 0.080 |
Why?
|
Hypertrophy | 1 | 2009 | 569 | 0.080 |
Why?
|
Smoking | 1 | 2004 | 8987 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 941 | 0.080 |
Why?
|
Hematopoiesis, Extramedullary | 1 | 2007 | 60 | 0.080 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2013 | 643 | 0.070 |
Why?
|
Survival Rate | 5 | 2017 | 12788 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2018 | 7279 | 0.070 |
Why?
|
Immunologic Factors | 1 | 2016 | 1580 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3508 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2010 | 498 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2023 | 13989 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2616 | 0.070 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6895 | 0.070 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 424 | 0.070 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5686 | 0.070 |
Why?
|
Mastectomy, Modified Radical | 2 | 2017 | 62 | 0.070 |
Why?
|
Filgrastim | 1 | 2006 | 133 | 0.070 |
Why?
|
Risk | 1 | 2018 | 9687 | 0.070 |
Why?
|
Radiation Injuries | 1 | 2013 | 1180 | 0.070 |
Why?
|
Constriction, Pathologic | 1 | 2009 | 1107 | 0.070 |
Why?
|
Metabolic Clearance Rate | 1 | 2006 | 380 | 0.070 |
Why?
|
Laboratories | 1 | 2009 | 463 | 0.070 |
Why?
|
Hormones | 2 | 2022 | 889 | 0.070 |
Why?
|
Contrast Media | 1 | 2019 | 5300 | 0.070 |
Why?
|
Pyrimidines | 2 | 2018 | 2942 | 0.070 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2759 | 0.060 |
Why?
|
Thyrotropin | 1 | 2009 | 849 | 0.060 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2009 | 324 | 0.060 |
Why?
|
Drug Evaluation | 1 | 2006 | 647 | 0.060 |
Why?
|
Arteries | 1 | 2010 | 1119 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6538 | 0.060 |
Why?
|
Young Adult | 6 | 2017 | 56430 | 0.060 |
Why?
|
Muscles | 1 | 2009 | 1614 | 0.060 |
Why?
|
Skull | 1 | 2008 | 813 | 0.060 |
Why?
|
Time Factors | 5 | 2019 | 40075 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1511 | 0.060 |
Why?
|
Bleomycin | 2 | 2017 | 512 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2021 | 12245 | 0.060 |
Why?
|
Vinblastine | 2 | 2017 | 502 | 0.060 |
Why?
|
Observer Variation | 1 | 2009 | 2593 | 0.060 |
Why?
|
Thrombocytopenia | 2 | 2010 | 1179 | 0.060 |
Why?
|
Doxorubicin | 3 | 2017 | 2234 | 0.060 |
Why?
|
Pelvic Neoplasms | 1 | 2005 | 254 | 0.060 |
Why?
|
Hernia, Inguinal | 1 | 2005 | 210 | 0.060 |
Why?
|
Piperazines | 1 | 2013 | 2488 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2018 | 3143 | 0.050 |
Why?
|
Edetic Acid | 1 | 2023 | 276 | 0.050 |
Why?
|
Mammography | 1 | 2013 | 2476 | 0.050 |
Why?
|
Kinetics | 3 | 2021 | 6473 | 0.050 |
Why?
|
Aromatase Inhibitors | 1 | 2006 | 491 | 0.050 |
Why?
|
Gallium Radioisotopes | 1 | 2023 | 178 | 0.050 |
Why?
|
Patient Care Team | 1 | 2013 | 2531 | 0.050 |
Why?
|
Toes | 1 | 2023 | 206 | 0.050 |
Why?
|
Drug Administration Schedule | 3 | 2017 | 4933 | 0.050 |
Why?
|
Dacarbazine | 2 | 2017 | 566 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1640 | 0.050 |
Why?
|
Surgery, Computer-Assisted | 1 | 2010 | 1018 | 0.050 |
Why?
|
Succinate Dehydrogenase | 1 | 2022 | 146 | 0.050 |
Why?
|
Tamoxifen | 1 | 2006 | 981 | 0.050 |
Why?
|
Thoracic Vertebrae | 1 | 2006 | 608 | 0.050 |
Why?
|
Organ Specificity | 1 | 2006 | 2008 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1836 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1375 | 0.050 |
Why?
|
Phantoms, Imaging | 1 | 2009 | 2480 | 0.050 |
Why?
|
Polyethylene Glycols | 1 | 2006 | 1182 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2503 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2008 | 6364 | 0.050 |
Why?
|
Melanoma | 1 | 2018 | 5510 | 0.050 |
Why?
|
Recombinant Proteins | 2 | 2009 | 6622 | 0.050 |
Why?
|
Abdomen | 1 | 2006 | 1118 | 0.050 |
Why?
|
Technetium Tc 99m Lidofenin | 1 | 2019 | 3 | 0.040 |
Why?
|
Spleen | 1 | 2006 | 2362 | 0.040 |
Why?
|
Forecasting | 1 | 2009 | 2951 | 0.040 |
Why?
|
Risk Factors | 3 | 2018 | 72290 | 0.040 |
Why?
|
Societies, Medical | 1 | 2012 | 3743 | 0.040 |
Why?
|
Monte Carlo Method | 3 | 2010 | 1254 | 0.040 |
Why?
|
Radioactive Tracers | 1 | 2019 | 72 | 0.040 |
Why?
|
Spinal Neoplasms | 1 | 2006 | 760 | 0.040 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2274 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2017 | 2242 | 0.040 |
Why?
|
United States | 3 | 2023 | 69872 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12354 | 0.040 |
Why?
|
Reoperation | 1 | 2008 | 4201 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2012 | 693 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4982 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 53288 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2009 | 19905 | 0.040 |
Why?
|
Consent Forms | 1 | 2018 | 53 | 0.040 |
Why?
|
Rectal Neoplasms | 1 | 2007 | 1206 | 0.040 |
Why?
|
Cytarabine | 1 | 2020 | 692 | 0.040 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2006 | 1524 | 0.040 |
Why?
|
Treatment Failure | 2 | 2015 | 2618 | 0.040 |
Why?
|
Disease Progression | 4 | 2016 | 13284 | 0.040 |
Why?
|
Maximum Tolerated Dose | 2 | 2010 | 892 | 0.040 |
Why?
|
Oligopeptides | 1 | 2023 | 1189 | 0.040 |
Why?
|
Pilot Projects | 2 | 2009 | 8324 | 0.040 |
Why?
|
Recurrence | 1 | 2008 | 8340 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8863 | 0.040 |
Why?
|
Indazoles | 1 | 2018 | 289 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2023 | 8949 | 0.030 |
Why?
|
Tissue Extracts | 1 | 2016 | 135 | 0.030 |
Why?
|
Career Choice | 1 | 2022 | 744 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2007 | 2541 | 0.030 |
Why?
|
Acute Disease | 1 | 2006 | 7149 | 0.030 |
Why?
|
Patient Selection | 2 | 2023 | 4215 | 0.030 |
Why?
|
Eating | 1 | 2022 | 1536 | 0.030 |
Why?
|
Anthracyclines | 1 | 2017 | 288 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2008 | 3327 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 127 | 0.030 |
Why?
|
Liver Neoplasms | 1 | 2010 | 4253 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 575 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 40561 | 0.030 |
Why?
|
Nausea | 1 | 2017 | 673 | 0.030 |
Why?
|
Rats | 2 | 2010 | 24260 | 0.030 |
Why?
|
Delayed-Action Preparations | 1 | 2017 | 968 | 0.030 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4149 | 0.030 |
Why?
|
Radiology | 1 | 2007 | 2100 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2118 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 574 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2023 | 3474 | 0.030 |
Why?
|
Animals | 4 | 2015 | 168757 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10943 | 0.030 |
Why?
|
Body Mass Index | 1 | 2009 | 12720 | 0.020 |
Why?
|
Models, Biological | 1 | 2008 | 9583 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 7023 | 0.020 |
Why?
|
Estrogen Receptor alpha | 1 | 2015 | 577 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2010 | 6773 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5751 | 0.020 |
Why?
|
B-Lymphocyte Subsets | 1 | 2012 | 246 | 0.020 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2012 | 169 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 309 | 0.020 |
Why?
|
Yttrium Radioisotopes | 1 | 2010 | 93 | 0.020 |
Why?
|
Vincristine | 1 | 2012 | 1039 | 0.020 |
Why?
|
Inflammation | 1 | 2009 | 10638 | 0.020 |
Why?
|
Predictive Value of Tests | 3 | 2010 | 15076 | 0.020 |
Why?
|
Pharyngeal Neoplasms | 1 | 2009 | 117 | 0.020 |
Why?
|
Necrosis | 1 | 2013 | 1643 | 0.020 |
Why?
|
Biopsy | 1 | 2021 | 6756 | 0.020 |
Why?
|
Tonsillar Neoplasms | 1 | 2009 | 51 | 0.020 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 408 | 0.020 |
Why?
|
Absorption | 1 | 2009 | 248 | 0.020 |
Why?
|
Leucovorin | 1 | 2010 | 628 | 0.020 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1333 | 0.020 |
Why?
|
Glucose Transporter Type 1 | 1 | 2009 | 192 | 0.020 |
Why?
|
Sulfonamides | 1 | 2018 | 1938 | 0.020 |
Why?
|
Clone Cells | 1 | 2012 | 1692 | 0.020 |
Why?
|
Adolescent | 4 | 2012 | 85781 | 0.020 |
Why?
|
Platelet Count | 1 | 2010 | 781 | 0.020 |
Why?
|
Tongue Neoplasms | 1 | 2009 | 180 | 0.020 |
Why?
|
Gastrointestinal Tract | 1 | 2013 | 814 | 0.020 |
Why?
|
Prednisone | 1 | 2012 | 1574 | 0.020 |
Why?
|
Research Design | 1 | 2023 | 5987 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2010 | 442 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2010 | 1588 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2012 | 1041 | 0.020 |
Why?
|
Neutropenia | 1 | 2012 | 895 | 0.020 |
Why?
|
Pedigree | 1 | 2014 | 4644 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 1619 | 0.020 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2012 | 570 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2008 | 675 | 0.020 |
Why?
|
Methotrexate | 1 | 2012 | 1727 | 0.020 |
Why?
|
Spinal Cord | 1 | 2013 | 1809 | 0.020 |
Why?
|
Models, Statistical | 2 | 2010 | 5102 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2008 | 1423 | 0.020 |
Why?
|
Fatigue | 1 | 2012 | 1531 | 0.020 |
Why?
|
Thorax | 1 | 2007 | 547 | 0.020 |
Why?
|
Quinazolines | 1 | 2010 | 1356 | 0.010 |
Why?
|
Internationality | 1 | 2009 | 1003 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1170 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2009 | 879 | 0.010 |
Why?
|
World Health Organization | 1 | 2009 | 1318 | 0.010 |
Why?
|
Bone and Bones | 1 | 2013 | 2575 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9313 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3689 | 0.010 |
Why?
|
Water | 1 | 2008 | 1395 | 0.010 |
Why?
|
Lung Diseases | 1 | 2012 | 1886 | 0.010 |
Why?
|
Lipid Metabolism | 1 | 2010 | 1889 | 0.010 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2009 | 3557 | 0.010 |
Why?
|
Temporal Lobe | 1 | 2008 | 1670 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2018 | 5256 | 0.010 |
Why?
|
Linear Models | 1 | 2010 | 5952 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2004 | 13102 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3309 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2014 | 11366 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2009 | 2109 | 0.010 |
Why?
|
Child | 1 | 2007 | 77709 | 0.010 |
Why?
|
Clinical Protocols | 1 | 2005 | 1462 | 0.010 |
Why?
|
Preoperative Care | 1 | 2007 | 2250 | 0.010 |
Why?
|
Neutrophils | 1 | 2010 | 3719 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2016 | 5181 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8436 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 29786 | 0.010 |
Why?
|
Data Collection | 1 | 2007 | 3341 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 5172 | 0.010 |
Why?
|
Software | 1 | 2010 | 4443 | 0.010 |
Why?
|
Lung | 1 | 2013 | 9856 | 0.010 |
Why?
|
Quality of Life | 1 | 2016 | 12804 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6196 | 0.010 |
Why?
|
Genetic Variation | 1 | 2009 | 6544 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10481 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 16689 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 13881 | 0.010 |
Why?
|
Brain | 1 | 2013 | 26385 | 0.000 |
Why?
|
Mice | 1 | 2009 | 81183 | 0.000 |
Why?
|